| 000 | 01268 a2200325 4500 | ||
|---|---|---|---|
| 005 | 20250515162051.0 | ||
| 264 | 0 | _c20090325 | |
| 008 | 200903s 0 0 eng d | ||
| 022 | _a1474-5488 | ||
| 024 | 7 |
_a10.1016/S1470-2045(09)70051-8 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBrizel, David M | |
| 245 | 0 | 0 |
_aTargeting the future in head and neck cancer. _h[electronic resource] |
| 260 |
_bThe Lancet. Oncology _cMar 2009 |
||
| 300 |
_a204-5 p. _bdigital |
||
| 500 | _aPublication Type: Letter; Comment | ||
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadministration & dosage |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 | _aBevacizumab |
| 650 | 0 | 4 |
_aCarcinoma, Squamous Cell _xdrug therapy |
| 650 | 0 | 4 |
_aErbB Receptors _xantagonists & inhibitors |
| 650 | 0 | 4 | _aErlotinib Hydrochloride |
| 650 | 0 | 4 |
_aHead and Neck Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aQuinazolines _xadministration & dosage |
| 650 | 0 | 4 |
_aVascular Endothelial Growth Factor A _xantagonists & inhibitors |
| 773 | 0 |
_tThe Lancet. Oncology _gvol. 10 _gno. 3 _gp. 204-5 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/S1470-2045(09)70051-8 _zAvailable from publisher's website |
| 999 |
_c18701937 _d18701937 |
||